Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus RICE or RVICI for relapsed or refractory pediatric mature B-cell non-Hodgkin lymphoma
NL-OMON50711Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), mature B-cell lymphoma and 1 more (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Ibrutinib pharmacokinetic exposure, Ibrutinib pharmacokinetic parameters and 2 more. Started Feb 2020; status: completed.
02
Drugs
ibrutinib
03
Conditions
Burkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphomaBurkitt leukemia
Beyond the preview
Go deeper on NL-OMON50711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50711.